In a small phase 2a trial published Oct. 24, 2026, in Nature Medicine, adding visugromab, which blocks the protein GDF-15, to nivolumab before bladder surgery led to no remaining cancer in 33% of patients vs. 8% with nivolumab alone.
In the VOLGA trial, published Oct. 24, 2026, in NEJM, people with muscle-invasive bladder cancer who couldn't get cisplatin had better event-free and overall survival when durvalumab and enfortumab vedotin were added around surgery.